Company Interview / Chimeric Therapeutics' global first

Rebecca McQualter of Chimeric Therapeutics shares updates on their cancer cell therapies.

She says the company are pioneering the use of 'off the shelf' stem core NK cells to treat acute myeloid leukaemia at MD Anderson Cancer Center. This marks a global first in cell therapy.

Rebecca explains that Chimeric is expanding its trials to Australia while also maintaining US operations. She explains that funding is solid with a $5M placement and a $4.1M R&D tax credit.

Chimeric is on track for Phase 2 trials next year, and Rebecca says several more announcements are ahead.